Rapamycin may extend life by changing calcium control of breathing-muscle contraction
In old mice, rapamycin may extend remaining life through calcium control of diaphragm contraction, independently of mechanistic target of rapamycin (mTOR) suppression or mitophagy. Benefit from genetic mTOR suppression after removal of the calcium effect would refute this explanation.
Stage of verification
- Hypothesis published2026-09-30
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Regulatory protein
FKBP12
A protein whose binding by rapamycin changes ryanodine receptor function and calcium entry
Where this hypothesis actsRespiratory muscles, particularly the diaphragm, in old mice
Hypotheses on this target 1
Inhibition
Activation
Lower level
Higher level
Protection from degradation
Function restoration
Function preservation
What is proposed
Deliver a ligand that binds FKBP12 and retains the proposed calcium effect
With whatSmall molecule
HowUse an FKBP12 ligand that preserves the required calcium action without suppressing mTOR; a specific ligand is not identified
Possible result
Possible increased diaphragm fatigue resistance and longer remaining life through delayed respiratory decompensation
From the recordЛиганд FKBP12, сохраняющий необходимое кальциевое действие и не подавляющий mTOR, воспроизводит оба эффекта.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
A longer life need not mean that aging has slowed across the body; it could mean that one life-limiting failure happens later. The unexpected move here is to attribute rapamycin’s proposed survival benefit mainly to better control of breathing-muscle contraction, rather than to the cellular maintenance route that motivated the question. This is a hypothesis generated by the pipeline, not a measured explanation of survival in old mice.
- Rapamycin is proposed to bind FKBP12 in breathing muscle.
- That binding is proposed to change calcium release through ryanodine receptors.
- The changed calcium control is proposed to help the diaphragm sustain repeated contractions.
- Greater resistance to fatigue is proposed to postpone failure of breathing.
- Postponing that failure is proposed to extend remaining life without reducing the transmission of damage between organs.
Keeping one worn-out pump working longer can keep a whole building usable even while its other systems continue to deteriorate.
Where the picture breaks: Organs influence one another, and better performance by one muscle does not establish which failure determines death. The picture also cannot explain why changing calcium release would improve endurance.
- Master questionstep 01 of 04
Processes involved in aging may reinforce one another, making a shared cause a possible target for benefits across several body systems.
Rests on: The goal seeks a single intervention capable of benefiting several systems by acting on a shared cause.
AssumptionThe search assumes that a shared causal link might be accessible to an intervention. The supplied goal does not establish that such a link exists or that targeting it extends life.
- Goal pillarstep 02 of 04
The intended output is a collection of life-extension ideas that work through distinct causes.
Rests on: The master question explicitly requests ideas for interventions acting on shared causes of aging.
Stated in the chain - Gap questionstep 03 of 04
Longer life after suppressing the mechanistic target of rapamycin, or mTOR, a cellular regulatory protein, might survive the loss of mitophagy, the removal of mitochondria, the cell structures involved in supplying energy. The question considers whether this benefit could come entirely from postponing one cause of death while damage continues to spread between organs at the same rate.
Rests on: The preceding goal calls for distinct causal explanations, but does not identify this particular intervention, proposed intermediary, or alternative explanation.
LeapThe supplied chain does not explain why mTOR suppression and mitophagy were selected from the broader search, or establish the presumed survival benefit and intermediary relationship. These are introduced as the setting for the question.
- Hypothesisstep 04 of 04
Rapamycin is proposed to extend remaining life in old mice mainly by changing calcium signals that control breathing-muscle contraction. Binding FKBP12, the 12-kilodalton FK506-binding protein, is proposed to alter ryanodine receptors, channels that release stored calcium inside muscle cells, and make the diaphragm, the main breathing muscle, resist fatigue. In this account, mTOR suppression accompanies the benefit but is unnecessary for it; postponing failure of breathing would not by itself meet the original requirement for benefits across several systems.S6S8S2
Rests on: The preceding question explicitly allows survival to improve through postponement of one cause of death despite blocked mitophagy. For the proposed molecular route, S6, a 1998 Nature study available here only through its abstract, reports that FKBP12 regulates calcium release through skeletal- and heart-muscle ryanodine receptors; it does not establish a rapamycin effect or a diaphragm or survival benefit. S8, a 1997 Neuroscience Letters study also available only through its abstract, reports altered channel opening when rapamycin binds and removes FKBP12 from rabbit skeletal-muscle receptors in artificial membranes; it does not establish fatigue resistance or survival in old mice. S2, a 2018 study in The Journal of Surgical Research, reports stronger diaphragm contractions with rapamycin in mechanically ventilated rats, whose breathing was supported by a machine; it does not establish fatigue resistance, the proposed calcium route, or longer life.
Supported by literature
What is carried, and what is not. Three screened sources provide partial support relevant to the proposed route: FKBP12 regulates calcium channels, rapamycin can alter those channels in an isolated preparation, and rapamycin was associated with stronger diaphragm contractions in ventilated rats. None establishes the complete sequence from that molecular action to fatigue resistance, postponed breathing failure, and longer life in old mice, or its independence from mTOR suppression and mitophagy.
Where the reasoning is carried by something unstated · 2
- Master question. The search assumes that a shared causal link might be accessible to an intervention. The supplied goal does not establish that such a link exists or that targeting it extends life.
- Gap question. The supplied chain does not explain why mTOR suppression and mitophagy were selected from the broader search, or establish the presumed survival benefit and intermediary relationship. These are introduced as the setting for the question. Establish the missing link before relying on this step.
How a result here could mislead · 3
- A difference between rapamycin and genetic mTOR suppression, meaning suppression produced by changing gene activity, could be credited to calcium control even if the two treatments suppress mTOR differently. Likewise, an additional FKBP12-binding compound could reproduce the outcome through effects other than the intended calcium action. What closes it: The comparison requires verified, comparable mTOR suppression in the relevant tissues and period, direct measurement of the intended calcium action, and evidence that selectively removing that action preserves mTOR suppression. The supplied proposal acknowledges that one additional drug cannot establish this separation and does not specify interventions that achieve it.
- A changed fluorescent marker could be mistaken for successful blockade of mitochondrial removal. One supplied rival explicitly predicts that acidity in lysosomes, cellular compartments that break down material, can change the marker signal without changing removal of whole mitochondria. What closes it: Blockade must be verified through evidence of actual mitochondrial removal alongside measurements that distinguish acidity-driven signal changes. The proposal requires confirmed blockade but supplies no verification method.
- Longer survival and a less fatigable isolated diaphragm could occur together without the muscle improvement causing the survival benefit. The competing explanations include delayed lethal tumor growth and protection of several tissues, either of which could account for survival through another route. What closes it: The work must establish whether breathing failure is actually postponed, assess competing causes of death, and show that selective removal of the calcium action removes the survival benefit while preserving mTOR suppression. Damage transmission between organs also requires its own measurement; survival and isolated-muscle performance cannot establish that it remains unchanged.
What would make this wrong. The proposed necessity of the calcium route would fail if its selective removal were verified, mTOR suppression remained intact, and the survival benefit nevertheless persisted. The supplied hypothesis also explicitly identifies continued benefit from genetic mTOR suppression after removal of that calcium action as a refuting observation. A survival benefit without improved diaphragm fatigue resistance or postponed breathing failure would break the claimed sequence linking muscle function to longer life.
What it would change. If the proposed separation of effects held, rapamycin’s survival benefit in the tested old mice would mainly reflect postponement of breathing failure through calcium control. Work seeking a shared cause of aging would then have to distinguish this route from an intervention that benefits several systems through a common cause. Even that result would not establish life extension in humans, the same dominant cause of death in other mouse populations, or a general slowing of aging.
Sources read · 6
Activation of mammalian target of rapamycin induces lipid accumulation in the diaphragm of ventilated rats and hypoxia-treated C2C12 cells. · The Journal of surgical research · 2018
“There was a significant increase in peak twitch and peak tetanic forces in the CMV+Rapa group compared with that in the CMV group”
Does not settle: Источник изучает крыс при искусственной вентиляции лёгких и клетки C2C12, а не старых мышей и продолжительность жизни. Он не исследует кальциевый контроль, FKBP12, рианодиновые рецепторы, утомление диафрагмы, митофагию, межорганную передачу повреждения или дыхательную декомпенсацию.
Activation of Calpain Contributes to Mechanical Ventilation-Induced Depression of Protein Synthesis in Diaphragm Muscle. · Cells · 2022
“overexpression of CAST and prevention of calpain activation did not protect against MV-induced decreases in the activation of both Akt and mTOR in diaphragm fibers.”
Does not settle: Источник не исследует рапамицин, FKBP12, рианодиновые рецепторы, кальциевый поток, утомляемость диафрагмы, продолжительность жизни старых мышей, митофагию или межорганную передачу повреждения.
Novel inhibition of contractility by wortmannin in skeletal muscle. · British journal of pharmacology · 1998
“Wortmannin inhibited contractures evoked by high K + , ryanodine and caffeine, but potentiated the contracture induced by rapamycin, which binds to myoplasmic FK506 binding protein, an immunophilin closely associated with the ryanodine receptor.”
Does not settle: Источник не устанавливает продление жизни у старых мышей, устойчивость диафрагмы к утомлению, причинную роль mTOR или митофагии, отсрочку дыхательной декомпенсации либо межорганные коэффициенты передачи повреждения.
Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. · Nature · 1998
“Physiological studies demonstrate that FKBP12 is dispensable for TGF-beta-mediated signalling, but modulates the calcium release activity of both skeletal and cardiac ryanodine receptors.”
Does not settle: Источник не устанавливает влияние рапамицина на работу рианодиновых рецепторов, сокращение или утомляемость диафрагмы, продолжительность жизни старых мышей, роль mTOR, митофагии или межорганной передачи повреждения.
Immunophilin Modulation of Calcium Channel Gating. · Methods (San Diego, Calif.) · 1996
“These effects were reversed by adding FK506 or rapamycin, both of which inhibit FKBP12 isomerase activity and dissociate the FKBP-RyR complex.”
Does not settle: Источник описывает эксперименты с клетками насекомых, ооцитами Xenopus laevis и реконструированными каналами. Он не устанавливает эффекты у старых мышей, продолжительность жизни, функцию или утомляемость диафрагмы, роль mTOR или митофагии, межорганную передачу повреждения и причинность предложенного механизма.
Ryanodine receptors from rabbit skeletal muscle are reversibly activated by rapamycin. · Neuroscience letters · 1997
“Irreversible channel activation and openings to subconductance levels are seen when rapamycin forms a complex with and removes the tightly bound 12 kDa FK506-binding protein (FKBP12) from the RyR.”
Does not settle: Источник описывает рианодиновые рецепторы скелетной мышцы кролика в липидных бислоях. Он не устанавливает продолжительность жизни старых мышей, работу диафрагмы и её устойчивость к утомлению, роль mTOR, митофагии или межорганной передачи повреждения.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Does blocking a growth-control protein still extend mouse life when damaged cell powerhouses cannot be cleared?
Original wording · exactly as the pipeline generated it
Сохранится ли продление жизни при подавлении mTOR после выключения предполагаемого посредника, митофагии, если межсистемное усиление повреждений останется прежним, а весь выигрыш объяснит отсрочка одной причины смерти?
What this question is asking
The question asks whether removing damaged energy-producing structures inside cells is necessary for a treatment to extend mouse life. It concerns suppression of mammalian target of rapamycin (mTOR), a protein involved in controlling cell growth, after disabling mitophagy, the process that removes those structures. The relevant comparison is whether suppression still increases remaining lifespan relative to no suppression when this removal process is disabled, compared with when it remains available. The question also considers a conditional explanation: damage in different body systems might continue to worsen other systems' damage, while the entire survival benefit comes from postponing just one cause of death.
- Mammalian target of rapamycin (mTOR)
- A protein involved in controlling cell growth. Suppression means reducing its activity; the question asks whether the resulting lifespan effect requires removal of damaged cellular powerhouses.
- Mitochondria
- Structures inside cells involved in producing usable energy, described here as cellular powerhouses. Their removal is the proposed link between treatment and longer life.
- Mitophagy
- The cellular process that removes mitochondria, including damaged ones. The question treats it as a possible necessary step in the lifespan effect, which the supplied sources do not establish.
- Autophagy
- The broader cellular process for removing and recycling material within cells. Mitophagy is the mitochondria-focused form; a finding about the broader process does not automatically establish the particular role of mitophagy.
- Mediator and mediation
- A mediator is an intermediate process through which an intervention causes an outcome. Here, mediation would mean that suppression of mTOR extends life through its effect on mitophagy, rather than the two simply being associated.
- Intersystem damage amplification
- The proposed process in which damage in one body system worsens damage in another. Its persistence during treatment is a condition considered by the question, not a finding established by the supplied sources.
- Rapamycin
- The treatment evaluated in the mouse lifespan findings quoted in S2. Those findings describe survival responses but do not establish the proposed role of mitophagy.
- Corylin
- The compound studied in S3. The supplied quotation reports a lifespan benefit in female mice without a comparable benefit in males.
- Median lifespan
- The time by which half of a studied group has died. It summarizes survival and does not identify which causes of death changed.
- Survival rate at a stated age
- The proportion of a group still alive at that age. S3 reports a comparison at 125 weeks; the supplied quotation does not give the underlying proportions.
- Mouse strain
- A mouse breeding line with a particular inherited background. S2 reports that strain influences the size of the lifespan response.
- Kisspeptin-10
- The molecule used in S5 to stimulate cellular removal processes. The supplied quotation describes a route independent of mTOR, so it does not establish mediation of a treatment that suppresses mTOR.
- Cellular signaling
- Processes through which activity in one part of a cell changes activity elsewhere in it. A signaling connection alone does not establish an effect on whole-animal lifespan.
- Human neuronal cell line
- Human cells maintained in laboratory culture and used to study nerve-cell processes. Findings in these cells do not by themselves establish survival effects in an animal.
- Hippocampus and cultured hippocampal tissue
- The hippocampus is a brain region. Cultured hippocampal tissue is tissue from that region maintained outside the animal; S5 includes this preparation alongside cell cultures and aging rats.
mTOR suppression is associated with longer mouse survival, mitophagy is its proposed cellular mediator, and the survival gain might occur with unchanged intersystem damage amplification because only one cause of death is delayed.
The proposed explanation places removal of damaged cellular powerhouses between blocking a growth-control protein and longer life. It contrasts protection across several body systems with a scenario in which damage still spreads between systems but one fatal condition occurs later. Establishing these links would distinguish a shared protective process from a narrower explanation of longer survival.
S2 reports generally favorable mouse lifespan findings for rapamycin, and S3 reports longer life in female mice receiving corylin. Neither supplied quotation establishes that removal of damaged cellular structures mediates those benefits. S5 instead reports stimulation of that removal through a route independent of mTOR; it does not establish the proposed mediation. None of the supplied sources establishes unchanged damage amplification between systems or a survival gain fully explained by delaying one cause of death. Those last conditions are hypothetical in the question, and this background-focused selection is too limited to establish or refute the complete premise.S2S3S5
The same question asked without the part nothing read establishes:
- Does suppressing the growth-control protein extend mouse life when removal of damaged cellular powerhouses is disabled?
- Does longer mouse life under suppression of the growth-control protein reflect lasting benefits across several body systems or postponement of one cause of death?
- The lifespan benefit persists Under the question's assumption that removal of damaged cellular powerhouses has been disabled, a persisting benefit would mean that this removal is not necessary for the entire survival effect. If postponement of one cause of death accounts for all of that benefit, longer life would not by itself demonstrate protection across several body systems.
- The lifespan benefit disappears Losing the benefit would be consistent with the removal process being necessary for the survival effect in the stated conditions. That result alone would still not establish that the process protects several systems or interrupts damage spreading between them.
- The lifespan benefit becomes smaller A smaller benefit would be consistent with the removal process contributing to, but not fully accounting for, longer survival. The remaining benefit would still need to be distinguished from the question's alternative explanation of postponing one cause of death.
The proposed explanation links suppression of the growth-control protein to removal of damaged cellular structures, then to lasting benefits across several body systems, and finally to longer life. Each connection matters because longer survival alone does not establish the preceding steps. Under the question's alternative explanation, postponing one fatal disease could extend life while damage elsewhere continues. Mistaking that outcome for protection across several systems would overstate what the survival findings establish.
Подавление mTOR уровня RL-2 связано с мышиной выживаемостью; митофагическое посредничество уровня RL-1 показано на клетках.
Выигрыш оставшейся жизни должен сопровождаться устойчивой пользой нескольким системам и проверенным общим посредничеством за единый горизонт наблюдения.
Не установлено, объясняет ли митофагия многосистемный выигрыш жизни; подавление отдельной смертельной патологии может воспроизводить наблюдаемую выживаемость.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
В проверяемой популяции старых мышей рапамицин продлевает жизнь преимущественно через изменение кальциевого управления сокращением дыхательных мышц. Связывание белка FKBP12 меняет работу рианодиновых рецепторов и поступление кальция, повышая устойчивость диафрагмы к утомлению. Подавление механистической мишени рапамицина (mTOR) сопровождает этот эффект, но для него причинно необязательно. Поэтому выигрыш сохраняется после выключения митофагии, а коэффициенты передачи повреждения между органами остаются прежними. Такая версия объясняет отсрочку дыхательной декомпенсации, однако сама по себе не удовлетворяет требованию многосистемной «серебряной пули».
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
При подтверждённой блокаде митофагии рапамицин сохраняет выигрыш оставшейся жизни и повышает устойчивость диафрагмы к повторным сокращениям. Сопоставимое подавление mTOR генетическим способом этого результата не воспроизводит. Лиганд FKBP12, сохраняющий необходимое кальциевое действие и не подавляющий mTOR, воспроизводит оба эффекта. Избирательное устранение кальциевого действия рапамицина отменяет выигрыш при сохранённом подавлении mTOR. Сохранение пользы генетического подавления mTOR после такого устранения опровергает гипотезу.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies observable lifespan and diaphragm endurance outcomes, qualitative comparisons across interventions, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Кальциевые ответы, силу и утомление изолированной диафрагмы можно измерить непосредственно. Главная трудность заключается в получении воздействий, разделяющих связывание FKBP12, кальциевые эффекты и подавление mTOR. Опыты с одним дополнительным препаратом такого разделения не обеспечивают.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
При подтверждённой блокаде митофагии рапамицин сохраняет выигрыш оставшейся жизни и повышает устойчивость диафрагмы к повторным сокращениям. Сопоставимое подавление mTOR генетическим способом этого результата не воспроизводит. Лиганд FKBP12, сохраняющий необходимое кальциевое действие и не подавляющий mTOR, воспроизводит оба эффекта. Избирательное устранение кальциевого действия рапамицина отменяет выигрыш при сохранённом подавлении mTOR. Сохранение пользы генетического подавления mTOR после такого устранения опровергает гипотезу.
- What would separate them
Growth-signal inhibition may release a brake on protein kinase B and limit cell death predicts: После блокады митофагии сохраняются краткий ответ AKT, уменьшение апоптоза после повторной нагрузки и замедление функционального ухудшения нескольких систем. Избирательное устранение вызванного лечением ответа AKT отменяет эти эффекты при сопоставимом подавлении mTOR. Модель, построенная по ответам на одиночные слабые нагрузки, заранее предсказывает меньший пик повреждения при их сочетании. Если защита сохраняется при устранённом ответе AKT либо измеренный ответ усиливает повреждение, гипотеза отвергается.
- Rival 02 of 04What would separate them
Lysosomal acidity may mimic faster mitochondrial removal predicts: Изменение сигнала mt-Keima объясняется независимо измеренной кислотностью и количеством ранее накопленного репортёра. После соответствующей калибровки увеличение потока исчезает; независимое отслеживание доставки и разрушения меченых митохондрий также не выявляет ускорения. При этом подавление mTOR замедляет рост опухоли даже после устранения дополнительных механизмов остальных гипотез. Длительные траектории заранее выбранных неопухолевых функций остаются прежними. Подтверждение ускоренного удаления целых митохондрий независимыми методами опровергает оптическую часть гипотезы.
- What would separate them
Reducing ribosomal gene transcription may protect tissues by limiting genome damage predicts: При подавленной митофагии лечение уменьшает гибриды РНК и ДНК и новые разрывы в рибосомных генах до появления функциональной пользы. Направленное удаление патологических гибридов рибонуклеазой H1 воспроизводит защиту и уменьшает дополнительный эффект рапамицина в диапазоне, свободном от потолочного эффекта. Избирательное восстановление исходного уровня гибридов при сохранённом подавлении mTOR отменяет защиту. Если лечение сохраняет функциональную и жизненную пользу при экспериментально восстановленном геномном повреждении, эта версия отвергается.
- Rival 04 of 04What would separate them
Ubiquitin-dependent protein disposal may preserve tissue function despite defective mitophagy predicts: После выключения митофагии сохраняются ускоренное разрушение заранее меченых повреждённых цитозольных белков и функциональная польза. Устранение именно вызванного лечением прироста убиквитин-зависимого разрушения отменяет пользу, хотя подавление mTOR и изменения транскрипции рибосомных генов сохраняются. Независимое восстановление протеасомного потока возвращает защиту. Сохранение пользы при отсутствии дополнительного разрушения соответствующих белков опровергает гипотезу.
Why this is not the mainstream account
The engine is asked to say what its hypothesis would overturn and what would surprise a specialist. This is its answer.
В первичной работе лиганды FKBP12, включая рапамицин и SLF, улучшали отдельные характеристики работы скелетных мышц; наблюдались изменения кальциевого обмена и устойчивости к утомлению. Продление жизни через этот путь работа не доказывает. [Исследование лигандов FKBP12](https://pmc.ncbi.nlm.nih.gov/articles/PMC4162161/).
Герофармакология, учебная глава «Питательные сигналы, mTOR и фармакологическое продление жизни». Пересмотра потребует причинная атрибуция выигрыша рапамицина подавлению mTOR в данной популяции.
Рапамицин сохраняет весь выигрыш жизни при экспериментально сохранённой активности mTOR, если кальциевое действие остаётся, тогда как изолированное подавление mTOR оказывается недостаточным.
В просмотренных источниках не найдено утверждения, что весь выигрыш жизни естественно стареющих мышей определяется кальциевым действием FKBP12 при причинно необязательном подавлении mTOR. Сами дополнительные мишени рапамицина уже обсуждаются. Поэтому необычность относится к полной причинной замене объяснения; отсутствие такой гипотезы во всей литературе не установлено.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.